Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [68Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer [0.03%]
前列腺癌患者中新型放射性药物[68Ga]Ga-OncoACP3-DOTA的药代动力学、剂量学及生物学分布的首次人体PET研究
Julia Brosch-Lenz,Florian Büther,Sebastian Oehler et al.
Julia Brosch-Lenz et al.
This study aimed to investigate the dynamics, pharmacokinetic characteristics, and radiation dosimetry of [68Ga]Ga-OncoACP3-DOTA, a novel prostatic acid phosphatase (ACP3)-targeted radioligand, in patients with metastatic castration-resista...
18F-FDG and 18F-Fluorocholine PET as Prognostic Biomarkers in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Prospective Multicenter Study [0.03%]
18F-FDG和18F-氟化氧胆碱正电子发射断层扫描在索拉非尼治疗晚期肝细胞癌患者中的预后价值：一项前瞻性多中心研究
Alexandre Cochet,Victor Besson,Aurélie Bertaut et al.
Alexandre Cochet et al.
The aim of this study was to evaluate the clinical significance of studies with dual radiotracers, 18F-FDG and 18F-fluorocholine (18F-FCH), performed before and after 1 mo of sorafenib therapy, in patients with advanced hepatocellular carci...
Biologic Definition of Parkinson Disease: A Pivotal Role for Molecular Imaging [0.03%]
帕金森病的生物学定义：分子影像的关键作用
Matthias Brendel,Henryk Barthel,Günter U Höglinger
Matthias Brendel
In this article, we outline the ongoing conceptual transition of Parkinson disease (PD) from a clinically defined syndrome to a biologically defined disorder. We synthesize recent advances in neuropathology, genetics, and biomarker research...
Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies [0.03%]
接受177Lu-PSMA联合治疗的患者中的血栓性微血管病
Joanna C Chan,Mitchell T Carroll,Nadia Hitchen et al.
Joanna C Chan et al.
Over a period of 10 y, our center treated 766 patients with prostate cancer using 177Lu-PSMA (177Lu-PSMA-617 or 177Lu-PSMA I&T). We report 5 cases of 177Lu-PSMA-induced thrombotic microangiopathy (TMA). Methods: In this retrospective analys...
From Anatomy to Theranostics: Toni Choueiri Talks with Ken Herrmann About the Evolution of Genitourinary Oncology [0.03%]
从解剖学到诊疗一体化：Toni Choueiri 谈论泌尿生殖系统肿瘤学的发展历程及对Ken Herrmann 的几点思考
Toni K Choueiri,Ken Herrmann
Toni K Choueiri
Quantitative Spatial Profiling of Antibody Delivery and Target Engagement Using Optically Labeled Antibodies [0.03%]
利用光学标记抗体进行抗体递送和作用靶点的定量空间定位分析
Hidenori Tanaka,Georgii Vasiukov,Candace J Grisham et al.
Hidenori Tanaka et al.
Visualization of drug distribution in human tumors is critical for optimizing biologic therapeutics, yet current clinical workflows cannot colocalize drugs and biomarkers on the same formalin-fixed, paraffin-embedded section. Methods: We pr...
Prognostic Value of [18F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer [0.03%]
使用视觉RECIP评估多西他赛治疗后的转移性前列腺癌的[18F]氟替夫单抗PET预后价值
Sonja Kirchhoff,Bernd Erber,Isabel Rauscher et al.
Sonja Kirchhoff et al.
We aimed to assess the prognostic value of [18F]flotufolastat PET in patients with metastatic prostate cancer during taxane-based chemotherapy (CTx). Methods: In total, 69 patients who received CTx as well as baseline and follow-up [18F]flo...
[177Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies [0.03%]
靶向CD44v6的放射性核素Lu-AKIR001治疗胰腺癌的药效学研究及联合用药策略探索
Amanda Gustafsson,Hedvig Svedberg,Sara S Rinne et al.
Amanda Gustafsson et al.
Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive, with a 5-y survival rate of less than 5% for patients with advanced disease. CD44v6 is frequently overexpressed in the malignancy, representing a promising therapeutic target. He...
PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability [0.03%]
前列腺特异性膜抗原正电子发射断层显像的剂量依赖性和肿瘤负荷驱动性变异
Akhilesh Mishra,Ala Lisok,Ronnie C Mease et al.
Akhilesh Mishra et al.
Prostate-specific membrane antigen (PSMA) is an attractive target for detection and treatment of prostate cancer because of its high, selective expression in tumors. However, PSMA-targeted antibody-drug conjugates (ADCs) have seen limited c...
Phase 1 Dose-Escalation Study of [225Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry [0.03%]
针对转移性去势抵抗性前列腺癌患者的[225Ac]Ac-PSMA I&T一期剂量递增研究：安全性、耐受性和剂量学分析
Sui Wai Ling,Mark Konijnenberg,Marcel Segbers et al.
Sui Wai Ling et al.
Radiopharmaceutical therapy with 225Ac-labeled prostate-specific membrane antigen (225Ac-PSMA) has shown promising results in patients with metastatic castration-resistant prostate cancer (mCRPC). To date, no phase 1 dose-escalation or comp...